London, Sept 10 (Patrika English News): Global pharmaceutical giant Merck has announced it will scrap its planned research operations in London, citing the UK’s increasingly difficult BUSINESS environment.
The company confirmed it will no longer proceed with its move into Belgrove House at King’s Cross, a site that had been slated to open in 2027. The decision is expected to affect about 125 staff members.
Instead, Merck said it will relocate the research activity to its existing sites, primarily in the United States, where pharmaceutical companies have been stepping up investment amid the Trump administration’s tariff threats and pressure to expand U.S. manufacturing.
In a statement, Merck said the move “reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life sciences industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments.”
The development marks another setback for the UK’s ambitions to become a global leader in life sciences and biotechnology investment.